Wall Street Analysts Give A Resounding 'Buy!' On AC Immune

AC Immune, which is a clinical stage biopharmaceutical firm, came out with its IPO in September. The company priced its IPO at $11.00 a share on September 22 and opened with 28 percent gain on the following day. The stock has traded between $13.01 and $19.97 since then.

Until now, the stock has already delivered more than 35 percent returns. Based on the three brokerage's least target price of $18, there is still upside potentials of about 18 percent. Similarly, the highest price objective of $25 reflected a possible upside of more than 60 percent.

Related Link: AC Immune Is An Alzheimer's Pure Play With A Lot On The Line

The following are the ratings and price objectives assigned by brokerages:

• Credit Suisse initiated with an Outperform rating with $18 as the price objective.
• Jefferies started with a Buy rating with a price target of $25.
• Leerink Swan commenced with an Outperform rating and a target price of $22.

At last check, AC Immune was up 5.47 percent at $15.22.

Full ratings data available on Benzinga Pro.